BOLT - Shareholder Alert: Robbins LLP Informs Stockholders of the Class Action Filed Against Bolt Biotherapeutics Inc. (BOLT) | Benzinga

SAN DIEGO, July 03, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of persons and entities that purchased or otherwise acquired Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) securities between February 5, 2021 and May 14, 2024. Bolt, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer.

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

The Allegations: Robbins LLP is Investigating Allegations that Bolt Therapeutics, Inc. (BOLT) Misled Investors Regarding the Viability of its New Drug Candidate

Plaintiff alleges that during the class period defendants failed to disclose to investors that: (i) BDC-1001 was less effective than the Company had represented to investors and was in fact unlikely to meet its pre-defined success criteria; (ii) accordingly, defendants overstated the clinical and/or commercial prospects of Bolt's product pipeline, on which the Company primarily relies to sustain its business model; and (iii) all of the foregoing subjected ...

BOLT)>Full story available on Benzinga.com